# Transgenic Mouse Genome Editing Core

> **NIH NIH P30** · UNIVERSITY OF PENNSYLVANIA · 2024 · $89,089

## Abstract

PROJECT SUMMARY (Transgenic Mouse Genome Editing Core)
The Transgenic Mouse Genome Editing Core (TMGEC) has been an integral part of the Diabetes Research
Center (DRC) at the Perelman School of Medicine, University of Pennsylvania since 1997. The TMGEC is
directed by Dr. Douglas Epstein, PhD, Professor and Vice Chair, Department of Genetics. Dr. Epstein is an
experienced investigator with considerable expertise in technologies and experimental approaches that center
on mouse models of disease, developmental genetics, and genome editing. An experienced technical team,
led by Dr. Jean Richa, provides expertise in a full range of transgenic technologies, enabling the TMGEC to
regularly introduce new and improved services. Services provided by the TMGEC include the generation of
genetically altered mice by direct genome editing (CRISPR/Cas9), DNA microinjection into fertilized oocytes to
create transgenic lines, the generation of chimeric mice via embryonic stem cell injection into blastocysts. The
TMGEC also carries out embryo re-derivation, embryo and sperm cryopreservation, in vitro fertilization (IVF),
and centralized cryopreservation storage. The TMGEC uses state-of-the-art laser conditioning of the zona to
facilitate IVF and has intracytoplasmic sperm injection capability to complement IVF services. Newly developed
services during the current funding period include the major expansion of cryopreservation services with
corresponding expansion of the cryopreservation facility, integration of CRISPR/Cas9 direct genome
modifications with a newly established Perelman School of Medicine CRISPR core, and electroporation of DNA
and RNA into embryos to increase throughput and decrease wait time for TMGEC services. In the past 5
years, 48 DRC investigators used TMGEC services to generate 225 independent mouse lines (primarily by
CRISPR/Cas9 editing) and to store 134 mouse lines (by cryopreservation). Usage is expected to stay the
same, or increase over the next five years. Additional Institutional (non-DRC) support is provided for equipment
maintenance and facility infrastructure upgrades and maintenance. An extensive network of collaborations
exist within the DRC focusing on the use of genetically modified mouse models of diabetes, obesity and
metabolic disorders. These joint projects among DRC investigators highlight the role of the TMGEC not only as
an essential technical resource but also as a key hub for collaborative research among DRC investigators, as
exemplified by the numerous joint publications and successful grant applications arising from mice generated,
stored, and/or re-derived by the TMGEC.

## Key facts

- **NIH application ID:** 10845595
- **Project number:** 5P30DK019525-48
- **Recipient organization:** UNIVERSITY OF PENNSYLVANIA
- **Principal Investigator:** DOUGLAS J EPSTEIN
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $89,089
- **Award type:** 5
- **Project period:** 1997-03-01 → 2027-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10845595

## Citation

> US National Institutes of Health, RePORTER application 10845595, Transgenic Mouse Genome Editing Core (5P30DK019525-48). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10845595. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*